AMGEN INC (AMGN) vs ELI LILLY & Co (LLY)
Side-by-side comparison from SEC filings: latest annual financials, insider activity and institutional ownership.
| Metric | AMGN | LLY |
|---|---|---|
| Sector | Health Care | Health Care |
| Latest fiscal year | FY2025 | FY2025 |
| Revenue | $36.75B | $65.18B |
| Revenue growth (YoY) | ▲ 10.0% | ▲ 44.7% |
| Net income | $7.71B | $20.64B |
| Gross margin | 67.2% | 83.0% |
| Diluted EPS | $14.23 | $22.95 |
| Insider net (6 mo) | +15.3K sh • 5 sells • 0 buys | −31.3K sh • 5 sells • 0 buys |
| Institutional owners | 46 | 51 |
| Institutional value held | $113.58B | $533.23B |
| Next earnings (est.) | Nov 3, 2026 | Around Oct 29, 2026 |
Figures from each company's SEC filings (latest reported fiscal year; fiscal calendars may differ). Next-earnings dates are estimates from historical filing patterns.
About AMGEN INC (AMGN)
Amgen Inc. is a global biotechnology company, incorporated in California in 1980 and reincorporated in Delaware in 1987, that discovers, develops, manufactures, and delivers innovative medicines targeting areas of high unmet medical need, operating as a… Read more →
About ELI LILLY & Co (LLY)
Eli Lilly and Company, incorporated in Indiana in 1901 and tracing its roots to a drug manufacturing business founded in 1876, operates as a single-segment human pharmaceutical company focused on discovering, developing, manufacturing, and marketing… Read more →
Source: SEC EDGAR.